Both drugs have been approved by the FDA for the treatment of treatment naïve and previously treated metastatic MET exon 14 skipping-altered NSCLC: capmatinib in 2020 and tepotinib in 2021 [147,148]. This evidence concerns the gene MET and non-small cell lung carcinoma.